BURLINGTON, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced positive topline clinical trial results from a Phase 2a synovial fluid PK study of FX006, which demonstrated, for the first time, that a single intra-articular (IA) injection of FX006 can provide therapeutic concentrations of drug in joint fluid for at least 12 weeks. FX006 is Flexion’s novel, non-opioid, sustained-release, IA formulation of TCA. It is designed to provide prolonged pain relief for the treatment of osteoarthritis (OA) of the knee, while potentially avoiding untoward systemic effects associated with immediate-release steroids.
Help employers find you! Check out all the jobs and post your resume.
